Annovis Bio Inc
(ANVS)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 15,286 | 17,130 | 22,236 | 10,552 | 12,637 |
| TOTAL | $17,189 | $21,455 | $26,737 | $13,926 | $14,362 |
| Non-Current Assets | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Assets | $17,189 | $21,455 | $26,737 | $13,926 | $14,362 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,112 | 974 | 1,370 | 2,306 | 4,099 |
| Accrued Expenses | 1,622 | 1,831 | 1,134 | 1,575 | 1,292 |
| TOTAL | $3,734 | $2,805 | $2,504 | $3,881 | $5,391 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 299 | 319 | 179 | 737 | 1,907 |
| TOTAL | $299 | $319 | $179 | $737 | $1,907 |
| Total Liabilities | $4,033 | $3,124 | $2,683 | $4,618 | $7,298 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 26,503 | 19,486 | 19,486 | 19,486 | 13,797 |
| Common Shares | 2 | 2 | 2 | 1 | 1 |
| Retained earnings | -153,869 | -146,607 | -140,387 | -134,850 | -128,985 |
| TOTAL | $13,156 | $18,331 | $24,054 | $9,308 | $7,064 |
| Total Liabilities And Equity | $17,189 | $21,455 | $26,737 | $13,926 | $14,362 |